Franck Bonnetain is a full Professor in epidemiology and biostatistics who received a master’s degree in clinical epidemiology from School of Public Health (Nancy, France). He obtained a PhD in public health with epidemiology and statistics specialties in 2005 as well asthe “Habilitation à diriger des recherches” (Professoral capability) in 2010. 



After working as epidemiologist for 3 years in Dijon for the “Institut de Veille Sanitaire”, he served as epidemiologist and biostatistician for the design, analyses and interpretation of clinical trials in Oncology. He was head of the methodology unit of French Federation of Digestive Cancerology (FFCD) and as head of methodology and quality of life unit of Georges François Leclerc Cancer care center from 2003 to 2012 (Dijon, France). Finally in September 2012 he was nominated as Professor in biostatistics, epidemiology, public health and quality of life in oncology at the university hospital of Besançon. He took the head of the methodology and quality of life in oncology unit.

In 2009, he launched and was co-founder of the French national clinical research plateform “Quality of life and cancer”.

He teaches statistics, epidemiology, methodology of clinical trials and quality of life in medical and pharmaceutical school as well as for master degree.


Research thematic:

Definition, selection and validation of endpoints used in oncology clinical trials

Health related quality of life and other Patient reported outcome in oncology

Design of clinical trials and epidemiological studies in oncology

Development of prognostic and predictive scoring system


Main areas of expertise:

- Methodology Statistics and clinical epidemiology

- Clinical trial and clinical research

- Quality of life

- Patient reported outcome

- Oncology

- Digestive Oncology

- Consensus methodology

- Supportive care


Main ongoing external collaborations:

- Full Member of EORTC QoL group since 2010 and board of Probe project since 2014

- Member of ARCAD Clinical Trials Program (http://arcad.marcelww.com/nos-actions/programmes-de-recherche/arcad-clinical-trials-program) and co-head of pancreatic cancer meta-analysis

- Head of DATECAN initiative (internal consensus for the definition of composite endpoints used in oncology clinical trials)

- Head of methodology of GERCOR since 2009 and member of PRODIGE group - Secretary of the AFSOS-UNICANCER French national supportive care group since 2013

- Referent Methodologist expert for GERICO (Geriatric oncology trials in France) and GI group of Unicancer

- Board of ANOCEF since 2010 (Association des neuro-oncologues d’expression française)

- Member of Cochrane lung cancer


Tools online

- Prognostic Score and Nomogram to Predict Overall Survival in Locally Advanced Pancreatic Cancer: The PROLAP score (mettre un lien qui renvoit sur l’outil)

Principaux articles

sample

AbstractPURPOSE:The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : JCO

sample

Background: In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN, Mme. Aurelia MEURISSE
Nom de la revue : JNCI J Natl Cancer Inst

sample

AbstractBACKGROUND:The combination of an anti-VEGF or an anti-EGFR-targeted monoclonal antibody with chemotherapy has...

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue : Lancet Oncol

Derniers articles

sample

Docetaxel, cisplatin, and 5-fluorouracil (DCF) significantly improved overall survival in metastatic...

Posté par : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY, Dr. Frederic FITENI
Nom de la revue : Cancer Medecine

sample

AbstractOverall survival (OS) has been considered as the most relevant primary endpoint but trials using OS often...

Posté par : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY, Dr. Dewi VERNEREY, Dr. Amélie ANOTA, , Dr. Frederic FITENI
Nom de la revue : Expert Review of Anticancer Therapy

sample

Background: In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN, Mme. Aurelia MEURISSE
Nom de la revue : JNCI J Natl Cancer Inst

sample

OBJECTIVES: The objective of this study was to explore the association between health-related quality of life (HRQoL)...

Posté par : Pr. Franck BONNETAIN, Dr. Amélie ANOTA
Nom de la revue : BMJ Open

sample

AbstractTraditionally, the efficacy of cancer treatment in patients with advance or metastatic disease in clinical...

Posté par : Pr. Franck BONNETAIN
Nom de la revue : Annals of Oncology

sample

Health-related quality of life (HRQOL) in cancer research is critical to more comprehensively evaluate patients’...

Posté par : Dr. Amélie ANOTA, Dr. Frederic FITENI, Pr. Franck BONNETAIN
Nom de la revue : Journal of Clinical Oncology

sample

Measures of health-related quality of life (HRQOL) and other patient-reported outcomes generate important data...

Posté par : Pr. Franck BONNETAIN
Nom de la revue : Lancet Oncology

sample

Abstract Background: Baseline prognostic biomarkers stratifying treatmentstrategies in first-line metastatic...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue :

sample

AbstractBackground The overexpression of human epidermal growth factor receptor-2 (HER2) in breast cancer is a poor...

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue : BMC Cancer

sample

In the Intergroupe Francophone de Cancérologie Thoracique 0501 trial the carboplatinpaclitaxel chemotherapy increased...

Posté par : Dr. Frederic FITENI, Dr. Amélie ANOTA, Pr. Franck BONNETAIN
Nom de la revue : European Respiratory Journal

Dernières actualités

Derniers outils

The R package QoLR allows to compute the scoring of main EORTC quality of life questionnaires and to perform the...

Posté par : Pr. Franck BONNETAIN, Dr. Amélie ANOTA

The R package QoLR allows to compute the scoring of main EORTC quality of life questionnaires and to perform the...

Posté par : Dr. Amélie ANOTA, Dr. Dewi VERNEREY, Dr. Amélie ANOTA, Pr. Franck BONNETAIN, Dr. Amélie ANOTA

The management of locally advanced pancreatic cancer (LAPC) patients remains controversial. Better discrimination for...

Posté par : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY, Dr. Dewi VERNEREY

MRQoL is a package that consists of three functions which allows us to calculate the Minimal Clinically Important...

Posté par : Pr. Franck BONNETAIN, Dr. Amélie ANOTA, Mr. Ahmad OUSMEN

The R package QoLR allows to compute the scoring of main EORTC quality of life questionnaires and to perform the...

Posté par : Dr. Amélie ANOTA, Dr. Dewi VERNEREY, Dr. Amélie ANOTA, Pr. Franck BONNETAIN, Dr. Amélie ANOTA

Communication from Pr Bonnetain at the 2nd EORTC Cancer Clinical Research Methodology Course for Patient Advocates,...

Posté par : Pr. Franck BONNETAIN

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY

Découvrez la présentation du Pr Bonnetain dans le cadre du séminaire du Cancéropôle Ile de France sur les tumeurs...

Posté par : Dr. Sophie PAGET-BAILLY, Pr. Franck BONNETAIN

Randomized Phase II Study of Weekly ABI-007plus Gemcitabine or Simplified LV5FU2 as FirstlineTherapy in Patients with...

Posté par : Pr. Franck BONNETAIN

2015-2018 © Copyright - UMQVC.org

Website by Pearlweb